Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Moshyk

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Acta Ophthalmologica|September 25, 2007
Depression and mortality in the visually-impaired, community-dwelling, elderly population of QuebecMarie Tournier, Yola Moride, Thierry Ducruet, et al.
Journal of Medical Economics|January 14, 2016
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in CanadaPeter Quon, Hoa H Le, Vincent Raymond, et al.
Clinical Biochemistry|June 18, 2005
When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?Ionela Gheorghiu, Andriy Moshyk, Raymond Lepage, et al.
Research Synthesis Methods|February 2, 2026
Incorporating the possibility of cure into network meta-analyses: A case study from resected Stage III/IV melanomaKeith Chan, Sarah Goring, Kabirraaj Toor, et al.
Experimental Hematology & Oncology|July 18, 2019
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanomaRavi Potluri, Sandip Ranjan, Hitesh Bhandari, et al.
BMC Cancer|January 6, 2021
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysisKabirraaj Toor, Mark R Middleton, Keith Chan, et al.
Future Oncology (London, England)|January 20, 2022
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanomaJames Signorovitch, Andriy Moshyk, Jing Zhao, et al.
Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.
Frontiers in Oncology|June 20, 2025
Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysisPeter Mohr, Murat Kurt, Swetha Srinivasan, et al.
Melanoma Management|January 27, 2025
Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature reviewCharmy Vyas, Andriy Moshyk, Gina Fusaro, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Acta Ophthalmologica|September 25, 2007
Depression and mortality in the visually-impaired, community-dwelling, elderly population of QuebecMarie Tournier, Yola Moride, Thierry Ducruet, et al.
Journal of Medical Economics|January 14, 2016
Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in CanadaPeter Quon, Hoa H Le, Vincent Raymond, et al.
Clinical Biochemistry|June 18, 2005
When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men?Ionela Gheorghiu, Andriy Moshyk, Raymond Lepage, et al.
Research Synthesis Methods|February 2, 2026
Incorporating the possibility of cure into network meta-analyses: A case study from resected Stage III/IV melanomaKeith Chan, Sarah Goring, Kabirraaj Toor, et al.
Experimental Hematology & Oncology|July 18, 2019
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanomaRavi Potluri, Sandip Ranjan, Hitesh Bhandari, et al.
BMC Cancer|January 6, 2021
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysisKabirraaj Toor, Mark R Middleton, Keith Chan, et al.
Future Oncology (London, England)|January 20, 2022
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanomaJames Signorovitch, Andriy Moshyk, Jing Zhao, et al.
Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.
Frontiers in Oncology|June 20, 2025
Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysisPeter Mohr, Murat Kurt, Swetha Srinivasan, et al.
Melanoma Management|January 27, 2025
Immune checkpoint inhibitors in pediatric patients with melanoma: a systematic literature reviewCharmy Vyas, Andriy Moshyk, Gina Fusaro, et al.
Pageof 3